CL2021001445A1 - Fórmula de entrega de medicamentos colónicos - Google Patents

Fórmula de entrega de medicamentos colónicos

Info

Publication number
CL2021001445A1
CL2021001445A1 CL2021001445A CL2021001445A CL2021001445A1 CL 2021001445 A1 CL2021001445 A1 CL 2021001445A1 CL 2021001445 A CL2021001445 A CL 2021001445A CL 2021001445 A CL2021001445 A CL 2021001445A CL 2021001445 A1 CL2021001445 A1 CL 2021001445A1
Authority
CL
Chile
Prior art keywords
colonic
drug
medication delivery
weight
core
Prior art date
Application number
CL2021001445A
Other languages
English (en)
Inventor
Felipe Varum
González Roberto Carlos Bravo
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of CL2021001445A1 publication Critical patent/CL2021001445A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación de fármaco de liberación retardada para administración oral para administrar un fármaco al colon de un sujeto. La formulación comprende un núcleo que comprende un fármaco y un revestimiento para el núcleo. El revestimiento comprende una capa exterior y una capa interior. La capa externa comprende un polímero entérico formador de película que tiene un umbral de pH de aproximadamente pH 6 o superior y la capa interna comprende un polímero no iónico formador de película que es soluble en líquido intestinal o gastrointestinal, y un agente tampón en una cantidad de más del 20% en peso a aproximadamente el 60% en peso, basado en el peso seco del polímero no iónico.
CL2021001445A 2018-12-07 2021-06-02 Fórmula de entrega de medicamentos colónicos CL2021001445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18211154.2A EP3662902B1 (en) 2018-12-07 2018-12-07 Colonic drug delivery formulation

Publications (1)

Publication Number Publication Date
CL2021001445A1 true CL2021001445A1 (es) 2022-01-21

Family

ID=64661235

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001445A CL2021001445A1 (es) 2018-12-07 2021-06-02 Fórmula de entrega de medicamentos colónicos

Country Status (27)

Country Link
US (1) US20220016038A1 (es)
EP (2) EP3662902B1 (es)
JP (1) JP7423630B2 (es)
KR (1) KR102777256B1 (es)
CN (1) CN113164401A (es)
AR (1) AR117682A1 (es)
AU (1) AU2019394086B2 (es)
BR (1) BR112021010915A2 (es)
CA (1) CA3122025A1 (es)
CL (1) CL2021001445A1 (es)
CO (1) CO2021008688A2 (es)
CR (1) CR20210365A (es)
EA (1) EA202191574A1 (es)
ES (1) ES2994844T3 (es)
GE (2) GEP20237517B (es)
IL (1) IL283721B2 (es)
JO (1) JOP20210135A1 (es)
MA (1) MA54373A (es)
MX (1) MX2021006693A (es)
MY (1) MY210540A (es)
PH (1) PH12021551291A1 (es)
SA (1) SA521422194B1 (es)
SG (1) SG11202105695WA (es)
TW (1) TWI827753B (es)
UA (1) UA128235C2 (es)
WO (1) WO2020115254A1 (es)
ZA (1) ZA202103678B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3662901B1 (en) 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
EP4382099A1 (en) 2022-12-05 2024-06-12 ADD Advanced Drug Delivery Technologies, Ltd. Drug loaded modified release pellets

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
FI20000780A7 (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
MX2009012030A (es) 2007-05-07 2010-01-25 Evonik Roehm Gmbh Formas farmacéuticas sólidas compuestas de un recubrimiento enterico con liberación acelerada del medicamento.
ES2655622T3 (es) * 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
CU24343B1 (es) 2012-04-30 2018-05-08 Tillotts Pharma Ag Formulación de fármaco de liberación retardada
AU2013404367B2 (en) * 2013-10-29 2020-02-27 Tillotts Pharma Ag A delayed release drug formulation
CN105412904A (zh) * 2014-06-17 2016-03-23 深圳翰宇药业股份有限公司 利那洛肽肠溶缓释微丸胶囊制剂及其制备方法和用途
CN105832691B (zh) * 2016-05-31 2018-10-02 深圳市健元医药科技有限公司 一种度拉糖肽结肠定位缓释制剂及其制备方法
JP7516007B2 (ja) 2016-06-28 2024-07-16 セリバ・バイオロジクス・インコーポレイテッド 経口抗生物質からのマイクロバイオーム防御
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation

Also Published As

Publication number Publication date
BR112021010915A2 (pt) 2021-08-24
AU2019394086B2 (en) 2025-02-27
CA3122025A1 (en) 2020-06-11
UA128235C2 (uk) 2024-05-15
TW202038915A (zh) 2020-11-01
CO2021008688A2 (es) 2021-07-30
CR20210365A (es) 2021-11-03
AR117682A1 (es) 2021-08-25
AU2019394086A1 (en) 2021-06-17
EP3662902C0 (en) 2024-07-31
US20220016038A1 (en) 2022-01-20
EP3890709A1 (en) 2021-10-13
EP3662902B1 (en) 2024-07-31
IL283721A (en) 2021-07-29
KR102777256B1 (ko) 2025-03-10
EA202191574A1 (ru) 2021-09-13
SA521422194B1 (ar) 2023-12-20
ES2994844T3 (en) 2025-02-03
WO2020115254A1 (en) 2020-06-11
KR20210100664A (ko) 2021-08-17
SG11202105695WA (en) 2021-06-29
IL283721B2 (en) 2025-08-01
EP3662902A1 (en) 2020-06-10
MA54373A (fr) 2022-03-16
JP7423630B2 (ja) 2024-01-29
GEAP202315682A (en) 2023-02-10
MY210540A (en) 2025-09-30
CN113164401A (zh) 2021-07-23
JOP20210135A1 (ar) 2023-01-30
IL283721B1 (en) 2025-04-01
TWI827753B (zh) 2024-01-01
PH12021551291A1 (en) 2022-03-28
MX2021006693A (es) 2021-09-23
GEP20237517B (en) 2023-06-26
JP2022511118A (ja) 2022-01-28
ZA202103678B (en) 2024-10-30

Similar Documents

Publication Publication Date Title
CO7141433A2 (es) Formulación de fármaco de liberación retardada
CO2021008688A2 (es) Fórmula de entrega de medicamentos colónicos
MX2020008017A (es) Formulaciones de vidrio y usos de las mismas.
JP2014240439A5 (es)
CL2021001472A1 (es) Formulación farmacéutica de liberación retardada que comprende una capa exterior con un polímero enzimáticamente degradable, su composición y su método de fabricación
MX2019002162A (es) Formulacion de farmaco de liberacion retardada.
MX2021011314A (es) Capsulas y recubrimientos de capsulas para formas de dosificacion de residencia gastrica.
AR108729A1 (es) Forma farmacéutica de unidades múltiples que comprende un núcleo con unidades centrales individuales cubiertas por un material muco-adhesivo, y un recubrimiento de núcleo entérico
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
CL2017001990A1 (es) Formulación de fármaco de liberación retardada (divisional solicitud 2796-2014)
AR111786A1 (es) Composiciones de gemcabeno y su uso
MX2021001397A (es) Sistema de nanoparticulas de dispersion mucoadhesiva y metodo de produccion del mismo.
MX2020006886A (es) Sistema para suministro de medicamento.
CU20140124A7 (es) Formulación de fármaco de liberación retardada
TH148827B (th) สูตรผสมยาชนิดปลดปล่อยแบบชะลอ
PH12018550075A1 (en) An oral osmotic pharmaceutical composition of vildagliptin
TH147933A (th) สูตรผสมยาชนิดปลดปล่อยแบบชะลอ
TH181888A (th) สูตรผสมยาชนิดปลดปล่อยแบบชะลอ
TH148827A (th) สูตรผสมยาชนิดปลดปล่อยแบบชะลอ
UA111566C2 (uk) Фармацевтична композиція пролонгованого вивільнення морфолінію [(5-метил-1н-1,2,4-триазол-3-іл)тіо]ацетату
PE20160211A1 (es) Formulacion de farmaco de liberacion retardada